News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline Says Advair Shows Edge over Spiriva in COPD
December 28, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - GlaxoSmithKline Plc said on Friday that clinical trial results showed its top-seller Advair had an edge over Pfizer Inc's (PFE.N: Quote, Profile, Research) rival product Spiriva in treating patients with the lung disease COPD.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Pfizer
GSK
MORE ON THIS TOPIC
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
April 2, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
April 2, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
April 2, 2026
·
5 min read
·
Angela Gabriel
